Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options
Company Announcements

Ocuphire Pharma Incentivizes Director Pepose with Stocks and Options

Ocuphire Pharma (OCUP) has issued an announcement.

Ocuphire Pharma, Inc. has engaged board director Dr. Jay Pepose as a consultant, compensating him with a monthly fee of $39,583, 32,000 restricted stock units, and options for 48,000 shares at $1.79 each. These incentives will vest over a year, incentivizing Dr. Pepose’s continued involvement with the company until the Consulting Agreement’s end date of April 11, 2025, signaling strategic moves that may interest stock market enthusiasts.

For an in-depth examination of OCUP stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyTwo new option listings and one option delisting on October 24th
TheFlyOcuphire Pharma price target lowered to $10 from $18 at Canaccord
TheFlyOcuphire Pharma rating placed under review at H.C. Wainwright
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App